Newsroom | 5436 results

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growi...

BOSTON--(BUSINESS WIRE)--Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced first patient enrollment in AI-PREDICT, a retrospective, international, multicenter study designed to establish a new lesion-centric paradigm for cardiovascular risk stratification. Enrollment is underway at three of more than 20 planned sites across the U.S., Europe, and Asia: Emory University, the Medical University of South Carolina, and Centro Cardiologico Monzino, Milan, led...

MIDDLETON, Wis. e LONDRA--(BUSINESS WIRE)--Leo Cancer Care, l'azienda specializzata in tecnologia medica impegnata a reinventare le modalità di diagnosi per immagini e di trattamento dei pazienti progettando sistemi basati sulla naturale posizione eretta del corpo, oggi ha annunciato la chiusura di un finanziamento di serie D da 65 milioni di dollari, sottoscritto in eccesso. Il round è stato condotto da Yu Galaxy, della Silicon Valley, e accoglie nuovi investitori, tra cui Eventide Asset Manag...

MIDDLETON, Wisconsin y LONDRES--(BUSINESS WIRE)--Leo Cancer Care, la empresa de tecnología médica que trabaja para reinventar la forma en que se obtienen imágenes y se trata a los pacientes a partir del diseño de sistemas basados en la posición vertical natural del cuerpo, anunció hoy el cierre de una ronda de financiación Serie D sobresuscrita por USD 65 millones. La ronda fue liderada por Yu Galaxy, de Silicon Valley, e incorpora nuevos inversores, entre ellos Eventide Asset Management, ademá...

MIDDLETON, Wis. & LONDEN--(BUSINESS WIRE)--Leo Cancer Care, het bedrijf gespecialiseerd in medische technologie dat zich inzet om de manier waarop aandoeningen van patiënten in beeld worden gebracht en behandeld volledig te herwerken door systemen rond de natuurlijke rechtopstaande houding van het lichaam te ontwerpen, maakte vandaag de afronding bekend van een overtekende Serie D-financiering van $65 miljoen. De financieringsronde werd geleid door Silicon Valley’s Yu Galaxy en verwelkomt nieuw...

MIDDLETON, Wisconsin et LONDRES--(BUSINESS WIRE)--Leo Cancer Care, société de technologies médicales qui réinvente la façon dont les patients sont imagés et traités en concevant des systèmes adaptés à la position verticale naturelle du corps, a annoncé aujourd'hui la clôture d'un tout de table de série D sursouscrit de 65 millions de dollars . Ce tour de table a été mené par Yu Galaxy, société de la Silicon Valley, et intègre de nouveaux investisseurs comme Eventide Asset Management, tout en co...

MIDDLETON, Wis. & LONDON--(BUSINESS WIRE)--Leo Cancer Care ist das Medizintechnikunternehmen, das daran arbeitet, Bildgebungsverfahren und Behandlungsmethoden für Patienten in aufrechter, natürlicher Position zu entwickeln. Es gab heute den Abschluss einer überzeichneten D-Finanzierungsrunde in Höhe von $65-Millionen bekannt. Die Runde wurde angeführt von Yu Galaxy und heißt neue Investoren willkommen wie Eventide Asset Management . Auch bestehende Investoren beteiligten sich erneut. Führende K...

MIAMI & BOSTON--(BUSINESS WIRE)--OpenEvidence and the Anticoagulation Forum (AC Forum) today announced a strategic partnership to provide antithrombotic guidance and tools that support decision-making in clinical practice. By combining the AC Forum’s leadership in education and multidisciplinary clinical guidance with OpenEvidence’s advanced artificial intelligence platform, clinicians will gain access to timely and practical evidence in antithrombotic therapy. “Clinicians are increasingly turn...

CHICAGO & ROCHESTER, Minn.--(BUSINESS WIRE)--GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer. This collaboration is a direct result of the 2023 Strategic Radiology Research Alliance between Mayo Clinic and GE HealthCare, aimed at transforming the experience of...

MIDDLETON, Wis. & LONDON--(BUSINESS WIRE)--Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions a...